BCAX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

BC

Mkt Cap

$1.11B

Volume

665.35K

Next Earnings

November 9th

Loading chart

BC

BCAXBicara Therapeutics Inc. Common Stock

BCAX

Pay with—

Available Balance0.00

BC

Mkt Cap

$1.17B

Volume

665.35K

Next Earnings

November 9th

Chart Financials Earnings News About Insider Filings

What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?Bicara Therapeutics CEO Claire Mazumdar sold 15,000 shares worth approximately $301,000 on May 18, 2026, through a pre-arranged Rule 10b5-1 trading plan adopted in February 2025. The sale reduced her direct holdings by 4%, but she retains 362,152 shares and 146,107 options, indicating continued substantial alignment with the company. The transaction appears routine for liquidity purposes rather than a sign of concern about the company's outlook.The Motley Fool · Jun 13, 2026

Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesBicara Therapeutics (NASDAQ: BCAX) successfully closed an oversubscribed public offering, raising approximately $172.5 million in gross proceeds through the sale of 8,581,250 common shares and 2,200,000 pre-funded warrants. The underwriters fully exercised their option to purchase additional shares. The company plans to use the proceeds to advance its lead program ficerafusp alfa, a first-in-class bifunctional antibody for solid tumors, including regulatory filing and commercial launch preparations, manufacturing costs, and clinical development acceleration.Benzinga · Feb 26, 2026

Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded WarrantsBicara Therapeutics priced a $150 million underwritten public offering of 7.175 million common shares at $16.00 per share and 2.2 million pre-funded warrants. The company plans to use proceeds to advance its lead candidate ficerafusp alfa, build commercial infrastructure, accelerate development in head and neck cancer, and fund manufacturing and expansion efforts. The offering is expected to close on February 26, 2026.GlobeNewswire Inc. · Feb 25, 2026

Bicara Therapeutics Announces Proposed Public Offering of Common StockBicara Therapeutics (NASDAQ: BCAX), a clinical-stage biopharmaceutical company, announced a proposed underwritten public offering of $150 million in common stock with a 30-day option for underwriters to purchase an additional $22.5 million. The company plans to use proceeds to advance its lead drug ficerafusp alfa, build commercial infrastructure, and support regulatory filings and commercial launch efforts.Benzinga · Feb 24, 2026

Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12Bicara Therapeutics will present at the J.P. Morgan 2026 Healthcare Conference, highlighting its lead program ficerafusp alfa, a bifunctional antibody designed to treat solid tumor cancers by targeting EGFR and TGF-β.GlobeNewswire Inc. · Dec 15, 2025

Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026Bicara Therapeutics reported promising Phase 1b data for ficerafusp alfa, a bifunctional antibody, in treating HPV-negative head and neck squamous cell carcinoma. The 750mg weekly dose showed a 57% confirmed overall response rate and was well-tolerated when combined with pembrolizumab.GlobeNewswire Inc. · Dec 6, 2025

Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in OncologyOncology drug delivery is advancing through nanomedicine technologies, with companies developing innovative platforms to improve drug bioavailability, reduce toxicity, and enhance therapeutic effectiveness in cancer treatments.Benzinga · Oct 27, 2025

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025Bicara Therapeutics presented updated data from its Phase 1/1b clinical trial of ficerafusp alfa in combination with pembrolizumab in patients with first-line recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). The data showed deep and durable responses, with a median duration of response of 21.7 months and a median overall survival of 21.3 months.GlobeNewswire Inc. · Jun 1, 2025

Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual MeetingBicara Therapeutics announced the publication of updated interim data from its Phase 1/1b trial of ficerafusp alfa in combination with pembrolizumab for first-line recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). The data will be presented at the 2025 ASCO Annual Meeting.GlobeNewswire Inc. · May 22, 2025

Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingBicara Therapeutics announced that updated data from its ongoing Phase 1/1b clinical trial of ficerafusp alfa in first-line recurrent/metastatic head and neck squamous cell carcinoma will be presented at the 2025 ASCO Annual Meeting.GlobeNewswire Inc. · Apr 23, 2025

to start trading

BC

BCAXBicara Therapeutics Inc. Common Stock

BCAX

Pay with—

Available Balance0.00

Your PositionYou don't own any BCAX yet.

Related Tickers

Earnings